| Jenni Herber | |
| (650) 826-2422 | |
| [email protected] |
| Margaret Tonda, PharmD | |
| (650) 741-7761 | |
| [email protected] |
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in
pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease. The primary
objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound)
measurements in SCD participants in this age range.
1. Male or female participants with Sickle Cell Anemia (SCA)
2. TCD time averaged maximum of the mean velocity (TAMMV) arterial cerebral blood flow ≥
170 to < 200cm/sec during the Screening Period
3. Hb ≥ 5.5 and ≤ 10.5 g/dL during screening
4. For participants taking HU, the dose of HU (mg/kg) must be stable for at least 90 days
prior to signing the informed consent form (ICF) and/or assent form, and with no
anticipated need for dose adjustments (other than weight based) or for initiation of
HU for non-chronic use during the study, in the opinion of the Investigator
5. Written informed parental/guardian consent and participant assent (where applicable)
has been obtained per IRB/EC policy and requirements, consistent with ICH guidelines.
1. Body weight < 5kg at the screening visit 2. Hospitalization for VOC or acute chest syndrome (ACS) within the 14 days prior to execution of informed consent/assent (see Section 7.2.5.1 for the definition of VOC). 3. More than 10 VOCs within the past 12 months that required hospitalization, emergency room, or clinic visit 4. Stroke resulting in focal neurological deficit; previous silent infarcts are permitted. 5. Known history or findings, including screening magnetic resonance imaging (MRI)/magnetic imaging angiography (MRA) findings, suggestive of significant cerebral vasculopathy (eg, moyamoya or significant vasculopathy) 6. History of seizure disorder (History of febrile seizures is permissible if there have been no seizures within the 12 months prior to randomization). 7. Has been treated with erythropoietin or other hematopoietic growth factors within 28 days of signing informed consent/assent or if, in the opinion of the Investigator, there is an anticipated need for such agents during the study 8. RBC transfusion therapy (also termed chronic, prophylactic, or preventative transfusion) or has received an RBC transfusion or exchange transfusion for any reason within 90 days of signing the informed consent/assent